Health

Des pas en alimentation durable mais trop petits pour bien nourrir tout le Qubec

Dévoilement de la politique bioalimentaire 2025-2035 August 22, 2025 12:52 ET  | Source: Collectif Vital MONTRÉAL, Aug. 22, 2025 (GLOBE…

5 months ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

August 22, 2025 17:30 ET  | Source: Celularity, Inc. FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc.…

5 months ago

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC:…

5 months ago

MEDIROM launches cryptocurrency strategy with next-generation proof of human technology, “World”

TOKYO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM) (the…

5 months ago

Financire de Tubize – Convening of the extraordinary general meeting of shareholders of Sep. 24, 2025

August 22, 2025 02:00 ET  | Source: Financière de Tubize SA Convening of the Extraordinary General Meeting of shareholders of…

5 months ago

Bavarian Nordic Announces First Half 2025 Results

COPENHAGEN, Denmark, August 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress…

5 months ago

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters Over-Allotment Option

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage…

5 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular…

5 months ago

Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%

COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to…

5 months ago